

Testing and Isolation Efficacy: Insights from a Simple Epidemic Model

May 6, 2021

1 Abstract

The effect of testing processes, including testing and test reporting, on an epidemic dynamics, involving infection and recovery, can be studied at the individual level or the community level (e.g., nursing homes, long-term-care facilities, etc.). Gaining insights to determine the sensitivity of the epidemic dynamics with respect to the testing processes will depend on underlying factors including the level of focus (individual or community), assumptions (model), and the interplay between these factors. In particular, the fast testing and test reporting may be beneficial at the community-level, supported by many studies, as it gives a rapid assessment of the situation, identifies hot spots, and may enable rapid contact-tracing. However, the potential advantage of a slow rate of test return on the dynamics of an epidemic is real, often neglected, and needs to be quantified. At the individual level, this advantage can manifest in the following sense: individuals awaiting their test results or who have tested positive may partially or fully self-isolate, thus reducing or eliminating their potential in the transmission process. In this paper, we investigated this individual-level effect of testing processes on the epidemic dynamics by developing a SIR-type model. Although the model development was motivated by the COVID-19 epidemic, the model has general epidemiological and testing structures. The realistic components of the model include *per capita* testing intensity, test sensitivity and specificity, rate of test return, and isolation efficacy in reduction of the probability of transmission. The novel component is the compartment-specific relative testing weights, which reflect the testing strategies—surveillance, diagnosis, or control. Here, we compare two testing strategies, random vs. targeted, and concluded that the targeted testing strategy is more effective in the sense that achieving reduction of \mathcal{R}_0 can occur in a lower range of testing intensity and longer test return time relative to the random testing. Furthermore, we show that increasing *per capita* testing intensity and reducing the test return time would be beneficial on the dynamics of an epidemic in general but there are exception cases. In particular, it is possible for the basic reproduction number, \mathcal{R}_0 , to be increasing with respect to the *per capita* testing intensity and the rate of test return when the isolation efficacy in reduction of the probability of transmission for awaiting individuals is loose.

2 Introduction

The observed dynamics of the COVID-19 epidemic are driven by both epidemiological processes (infection and recovery) and testing processes (testing and test reporting). In addition to shaping epidemic observations (via case reports), testing processes can also affect epidemiological dynamics. In particular, individuals with confirmed infections (positive tests) are likely to self-isolate, and individuals who are awaiting the results of a test may do so also (possibly to a lesser extent). We developed a mechanistic model that incorporates epidemic processes and testing in order to explore the effects of testing and isolation on epidemic dynamics.

If testing influences behavior, then epidemic dynamics will depend on patterns of who gets tested. The impacts of testing will depend on intensity (tests performed per day), and on how strongly testing is focused on people who are infectious. This level of focus depends in turn on the purpose and design of testing programs. When testing is done for the purposes of disease surveillance (Foddai et al., 2020) tests should be assigned randomly across the population, possibly with a stratified design for statistical efficiency (Graubard and Korn, 1996) [Ali: a better ref everyone?].

Over the course of the COVID-19 pandemic, however, the vast majority of testing has been done with other goals – primarily diagnosis (determining the infection status for clinical purposes), or control (determining the infection status in order to quickly isolate cases that have been found by contact tracing), which we characterize as *targeted* testing strategies. In these cases, testing probabilities vary widely across epidemiological compartments; in our dynamical model, we will characterize these probabilities by assigning a *per capita* testing weight to each compartment that determines the *relative* probability that an individual in that compartment will be selected for testing (see Methods).

When testing is used primarily for diagnosis it will focus on people with infection-like symptoms; thus the relative testing weights for infected people will depend on the relative probability of infected people having symptoms. For COVID-19 infection, the testing weights will depend on the relative asymptomatic infections, time spent pre-symptomatic vs. symptomatic infections – and also the incidence of COVID-19-like symptoms among people in the population *not* infected with COVID-19. Testing for epidemic control will focus on people who are known to have been in contact with known infected cases; in this case the testing weights for infected vs. uninfected people will depend on the probability of infection given contact, as well as the thoroughness and effectiveness of the system for identifying suspicious contacts.

The main interest from the epidemiological point of view is to know whether the number of infected individuals goes through an exponential growth phase, following the introduction of an infection in a totally susceptible population, before the disease becomes extinct. This is determined by studying the basic reproduction number \mathcal{R}_0 . It is defined as the expected number of secondary infections arising from a typical infective individual in a completely susceptible population (Dietz, 1993). In the early stages of an epidemic the number of infected individuals is expected to grow exponentially over time when $\mathcal{R}_0 > 1$, and to decline over time when $\mathcal{R}_0 < 1$. Although the value of \mathcal{R}_0 cannot completely characterize the dynamics of even the simplest epidemic model (Shaw and Kennedy, 2021), it does give a simple and widely accepted index for the difficulty of control, as well as some indication

of the likely final size of an epidemic (Ma and Earn, 2006).

In order to understand the effect of testing processes on an epidemic dynamics, we developed a mechanistic SIR-type model with epidemic and testing components. This model provides a sensible platform to link the modeling of epidemic and testing components and study their interaction. Here, we studied the effect of testing intensity, rate of test return and the isolation efficacy in reduction of the probability of transmission on the epidemic dynamics when different levels of testing “focus” (from random to highly targeted) are in place. Our model provides insights to the sensitivity of the epidemic dynamics, through \mathcal{R}_0 , with respect to the underlying testing and isolation parameters. [Ali: edited in response to David comments.]

3 Methods

We developed a deterministic model, Eqs. (A1), which groups individuals based on disease status and testing status. Disease states include Susceptible, Infectious and Recovered (thus this is an SIR-type model), and testing status categorizes people as *untested*, *waiting-for-positive*, *waiting-for-negative*, or *confirmed positive* (Figure 1). Symbolically, the testing status of an individual in the disease compartment X , where $X \in \{S, I, R\}$, is reflected in the subscript, namely X_u , X_p , X_n and X_c , for *untested*, *waiting-for-positive*, *waiting-for-negative*, or *confirmed positive*, respectively. Note that the top-to-bottom order of the testing-based compartments of each disease-based compartment X in the flowchart (Figure 1) and the model equations (A1) should match. However, we switched X_u and X_n in the flowchart (Figure 1) for the sake of tidiness of the flowchart. Further, two ‘accumulator’ compartments, N and P , were also incorporated in the model in order to collect cumulative reported negative or positive tests. The model equations and details of calculation of the basic reproduction number \mathcal{R}_0 are presented in the appendix (see Sec. 5.1).

Table 1 defines the model parameters, which are generally straightforward *per capita* flows between compartments, or modifiers to these flow rates. The novel component of the model comes in through the compartment-specific relative testing weights w_S , w_I and w_R ; these give the relative rates at which people in the S , I , and R compartments are tested, respectively. Thus, we can specify different levels of testing “focus” from random to highly targeted. For example, $w_I/w_S = 2$ means that infected individuals are tested at twice the *per capita* rate of susceptible individuals.

In order to link to more applied models, we constructed this model so we could specify the total *per capita* testing rate. We do this by defining the weighted size of the testing pool $W = w_S S_u + w_I I_u + w_R R_u$, and calculating a scaling parameter for testing as:

$$\sigma = \frac{\rho N_0}{W}, \quad (1)$$

where ρ is the *per capita* testing intensity for population and defined as the number of daily tests taken in a population of size N_0 . Thus, the *per capita* testing rate for compartment X is

$$F_X = \sigma w_X, \text{ where } X \in \{S, I, R\}. \quad (2)$$




Figure 1: Flowchart of the SIR (Susceptible-Infectious-Recovered) model, A1. Here, the disease-based status of a compartment X , where $X \in \{S, I, R\}$, is combined with the testing-based status including X_u , X_p , X_n and X_c , for *untested*, *waiting-for-positive*, *waiting-for-negative*, or *confirmed positive*, respectively. Also, Λ is the force of infection with definition in Eq. (3), γ is the recovery rate, ω is the rate of test return, F_X (defined in Eq. (2)) and p_X represent the *per capita* testing rate and the probability of positive tests, respectively, for compartment X . For further description of the parameters see Table 1.

For a high-sensitivity test, infected people typically flow through to the “confirmed positive” (I_c , R_c) compartments and are thus unavailable for further testing. Over the course of the epidemic, a fixed testing rate as specified in (1) can (if large enough) exhaust the pool of people available for testing, leading to a singularity when no one is left untested. Although this phenomenon does not affect our analysis of \mathcal{R}_0 , it can affect the temporal dynamics (we discuss an adjustment to the model that solves this problem in the appendix).

The classical SIR model is based on the following implicit assumptions; well-mixed population, homogeneity of the population (i.e., all individuals are equally susceptible and equally infectious for the same length of time when infected), exponentially distributed duration of infection and large population size (see, e.g., Keeling and Rohani (2011)). In addition to these standard assumptions, our model, A1, assumes: (i) there is a single force of infection (new cases per unit time), Λ , defined as follows

$$\Lambda = \frac{\beta}{N_0} (I_u + (1 - \theta_w)(I_n + I_p) + (1 - \theta_c)I_c), \quad (3)$$

across all susceptible pools with transmission rate β and isolation efficacy in reduction of the probability of transmission for three testing-based compartments “waiting” and *confirmed positive* individuals, θ_w and θ_c respectively, (see Table 1 for further details), (ii) $\theta_w \leq \theta_c$, i.e., the individuals awaiting test results have a higher transmission probability than the reported individuals. Thus, for instance when the awaiting people follow the isolation perfectly, θ_w is closer to 1, while when they less follow the isolation, θ_w is closer to 0. For this analysis, we also assume a perfectly specific test ($p_S = 0$). This last assumption combined with the assumption that no susceptible individual is in waiting-for-*positive* or *confirmed positive* compartments, i.e., $S_p(0) = S_c(0) = 0$, reduces the model to 10 equations where equations c and d in model (A1) are eliminated.

The Disease-Free Equilibrium (DFE) for the SIR model, Eqs. (A1), is found by setting the infected compartments to 0 and solving for the unknowns. The DFE is

$$S_n^* = \frac{\rho}{\omega} N_0, \quad S_u^* = \frac{\omega - \rho}{\omega} N_0, \quad \text{and} \quad I_j = R_j = 0 \quad \text{for all } j. \quad (4)$$

The corresponding *per capita* testing rate (Eq. 2) for the infected compartment I at DFE is one of the key analysis parameters and can be simplified as

$$\hat{F}_I = (\omega\rho/(\omega - \rho))w_I/w_S. \quad (5)$$

The basic reproduction number, \mathcal{R}_0 , was calculated by using the next generation matrix method developed by van den Driessche and Watmough (2002). \mathcal{R}_0 is

$$\mathcal{R}_0 = \frac{\beta}{\gamma}(1 - \Delta), \quad (6)$$

where the term $\frac{\beta}{\gamma}$ is the classical basic reproduction number for a SIR model without testing and isolation (see, e.g., Keeling and Rohani (2011)), and Δ is the reduction parameter defined as follows. **[Ali: Δ should be updated, the expression will be linear in θ_c but quadratic in**

Symbol	Description	Unit	Value
N_0	Total population size	people	10^6
ω	Rate of test return, i.e., rate of onward flow from “waiting” to “confirmed” or “untested” compartments	1/day	-
γ	Recovery rate	1/day	1/3
ρ	<i>per capita</i> testing intensity	1/day	-
θ_w	Isolation efficacy in reduction of the probability of transmission for “waiting” individuals	-	-
θ_c	Isolation efficacy in reduction of the probability of transmission for “confirmed positive” individuals	-	-
β	Transmission rate	1/day	0.339
Λ	Force of infection	1/day	-
p_S	Probability of positive tests for S ($= 1 - \text{specificity}$)	-	0
p_I	Probability of positive tests for I ($= \text{sensitivity}$)	-	1
p_R	Probability of positive tests for R ($= 1 - \text{specificity}$)	-	0.5
w_S, w_I, w_R	Relative testing weights	-	Random: $\{1, 1, 1\}$ Targeted: $\{0.3, 1, 1\}$

Table 1: Parameters of the model (A1).

θ_w , C stay unchanged. It can be proved that Δ increases in θ_w for feasible range of θ_w (I think this argument will go to the appendix).?]]

$$\Delta = (A \theta_w + B \theta_c)/C, \quad (7)$$

where

$$\begin{aligned} A &= \gamma \left((\gamma(\omega + \gamma) + \omega p_I \hat{F}_I) \frac{(1 - \theta_w) S_n^*}{N_0} + (\omega + \gamma) \hat{F}_I \right), \\ B &= \omega p_I \left(\gamma \frac{S_u^*}{N_0} + \omega \right) \hat{F}_I, \\ C &= (\omega + \gamma) \left(\gamma(\omega + \gamma) + (\gamma + \omega p_I) \hat{F}_I \right). \end{aligned} \quad (8)$$

Further details of derivation of \mathcal{R}_0 are provided in section 5.1 of the appendix. Note that Δ has been presented in a specific monotonic form with respect to isolation efficacy parameters, θ_w and θ_c , in order to simplify showing one of the results of this paper which is the reduction effect of isolation on \mathcal{R}_0 . Further, we represent Δ in another equivalent form in the appendix (Sec. 5.2) to show the nontrivial-nonmonotonic effect of testing intensity and test return rate on \mathcal{R}_0 .

The analytical calculation of the next-generation matrix and simplifying the expression of \mathcal{R}_0 was carried out in Maple (Maplesoft, 2010). We used R (R Core Team, 2020) for simulations, in particular, for plotting the contours of Δ (7) over a range of selected set of parameters of interest, i.e., parameters that could be manipulated by public-health policy. These parameters include the isolation efficacy parameters, θ_c and θ_w , *per capita* testing intensity, ρ , and the rate of test return, ω . The rest of model parameters kept fixed at sensible values (see Table 1 for the parameter values). Note that all plots are illustrated in the scale of the mean test return time $1/\omega$ (day). Results are shown in Fig. 2 and Fig. 3 with two panels; panel (a) represents the random testing, thus $w_S = w_I = w_R = 1$, and panel (b) represents targeted testing, thus $w_S = 0.3$ and $w_I = w_R = 1$. To illustrate the changes in \mathcal{R}_0 with respect to *per capita* testing intensity ρ , two sets of plots are presented. Fig. 2 reflects the changes in \mathcal{R}_0 when ρ is small relative to the population size. Specifically, $\rho \in [0, 0.01]$, and the test return rate $\omega \in [0.1, 2]$. This is a more realistic scenario of testing as we have observed in COVID-19 pandemic. That is, 1% of a population are tested per day at maximum capacity, so in a population of size $N_0 = 10^6$, 10000 individuals will be tested per day at maximum. In order to illustrate the non-monotonic changes in \mathcal{R}_0 with respect to ρ , Fig. 3 with maximum capacity of ρ is larger relative to the population size, $\rho \in [0, 0.5]$, and the test return rate $\omega \in (0.5, 2]$. In both Fig. 2 and Fig. 3, the isolation efficacy parameters, θ_w and θ_c vary from 0 to 1. Note that the critical contour of $\Delta = 1 - \frac{\gamma}{\beta}$, corresponding to the threshold $\mathcal{R}_0 = 1$, is plotted in solid line in the panels. Thus, a combination of ρ and ω above this critical contour results in reducing \mathcal{R}_0 . Also realize that $\mathcal{R}_0 = \frac{\beta}{\gamma}$, about 1.017 here, for the classical SIR model which can be achieved in the context of our model when $\rho = 0$, no testing, or $\theta_w = \theta_c = 0$, no isolation.

4 Results

The explicit formula for the basic reproduction number, \mathcal{R}_0 (6), provides an opportunity to study the influence of changes in the underlying parameters of interest on the critical index

of epidemic dynamics. These parameters include the isolation efficacy parameters, θ_c and θ_w , *per capita* testing intensity, ρ , and the rate of test return, ω . In this context, two testing strategies, namely random and targeted testing, were explored.

Examining our formula for \mathcal{R}_0 (6) gives the following results. See the appendix, Sec. 5.2 and Sec. 5.3 for details.

1. Increasing the isolation parameters for tested and confirmed individuals decreases \mathcal{R}_0 ;
2. Higher testing ρ intensity always decreases \mathcal{R}_0 **if**: testing is random; **or** ρ is small.
3. A higher rate of test return always decreases \mathcal{R}_0 , **if** $\theta_w = 0$.




Figure 2: **A comparison of the behaviour of the basic reproduction number, \mathcal{R}_0 , between random versus targeted testing strategies at different levels of testing and isolation.** We numerically evaluate Δ (6), reflecting the reduction of \mathcal{R}_0 with respect to testing and isolation. We use the following parameters (see Table 1): $N_0 = 1 \times 10^6$, $\omega \in [0.1, 2]$ 1/day, $1/\gamma = 3$ days, $\rho \in [0, 0.01]$ 1/day, θ_w and θ_c vary between 0 and 1 with 0 for no effect and 1 for full effect of isolation on the transmission probability, $\beta = 0.339$ 1/day, $p_S = 0$, $p_I = 1$ and $p_R = 0.5$. Contours of Δ are plotted for two testing strategies identified by a set of relative testing weights; (a) random testing where $w_S = w_I = w_R = 1$ and (b) targeted testing where $w_S = 0.3$ and $w_I = w_R = 1$. The black dotted line in each panel represents the critical contour of $\Delta = 1 - \frac{\gamma}{\beta}$, i.e., the Δ corresponding to the threshold of $\mathcal{R}_0 = 1$.

Numerical results are shown in Fig. 2. Targeted testing (panel b) is more effective at control than random testing (panel a).

When $\theta_w = 0$ (top row of each panel), we see that shorter test-waiting times reduce \mathcal{R}_0 (Δ increases as we move to the left in each plot in this row). For non-zero Δ , however,




Figure 3: **A comparison of the behaviour of the basic reproduction number, \mathcal{R}_0 , between random versus targeted testing strategies at different levels of testing and isolation.** We numerically evaluate Δ (6), reflecting the reduction of \mathcal{R}_0 with respect to testing and isolation. We use the following parameters (listed in Table 1): $N_0 = 1 \times 10^6$, $\omega \in (0.25, 2]$ 1/day, $1/\gamma = 3$ days, $\rho \in [0, 0.25]$ 1/day, θ_w and θ_c vary between 0 and 1 with 0 for no effect and 1 for full effect of isolation on the transmission probability, $\beta = 0.339$ 1/day, $p_S = 0$, $p_I = 1$ and $p_R = 0.5$. Contours of Δ are plotted for two testing strategies identified by a set of relative testing weights; (a) random testing where $w_S = w_I = w_R = 1$ and (b) targeted testing where $w_S = 0.3$ and $w_I = w_R = 1$. The black solid line in each panel represents the critical contour of $\Delta = 1 - \frac{\gamma}{\beta}$, i.e., the Δ corresponding to the threshold of $\mathcal{R}_0 = 1$. **[BMB: we still have some collisions in the y-axis tick labels]**

we mostly see the opposite effect: less waiting leads to more transmission. This is because returning negative tests leads people to stop distancing; this applies both to susceptibles, and to infectious people who receive negative test results because they were sampled when susceptible (or because of imperfect test sensitivity, which is not modeled in this figure).

We also see that greater test intensity ρ increases the effectiveness of control Δ (Δ increases as we move up in each plot in this Figure. Mathematically speaking, we did find a counter-vailing effect, but this can only be seen when we allow ρ to take unrealistically large values, and only for weighted testing (see Fig. 3). The explanation here is that more rapid testing leaves more susceptibles in the “waiting-for-no” category at the DFE; these people must then wait for their tests to be returned before they can be tested again, receive a positive test, and become cautious. This effect is usually weak compared to the helpful effects of testing, but if testing is weighted, θ_w is low, and test returns are slow, it is possible for increasing ρ to reduce Δ (see upper-right part of upper-right plot of Fig. 3(b)).

5 Discussion

The counter-vailing effect of *per capita* testing intensity, ρ , on \mathcal{R}_0 ; - we are missing out on community-level advantages of fast testing.

The potential advantage of slow test reporting, or favorable-delay-reporting;

References

Dietz, K. (1993). The estimation of the basic reproduction number for infectious diseases. *Statistical methods in medical research*, 2(1):23–41.

Foddai, A., Lubroth, J., and Ellis-Iversen, J. (2020). Base protocol for real time active random surveillance of coronavirus disease (COVID-19)—adapting veterinary methodology to public health. *One Health*, page 100129.

Graubard, B. I. and Korn, E. L. (1996). Modelling the sampling design in the analysis of health surveys. *Statistical methods in medical research*, 5(3):263–281.

Keeling, M. J. and Rohani, P. (2011). *Modeling infectious diseases in humans and animals*. Princeton University Press.

Ma, J. and Earn, D. J. D. (2006). Generality of the final size formula for an epidemic of a newly invading infectious disease. *Bulletin of Mathematical Biology*, 68(3):679–702.

Maplesoft (2010). *Maple (14)*. a division of Waterloo Maple Inc., Waterloo, Ontario.

R Core Team (2020). *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria.

Shaw, C. L. and Kennedy, D. A. (2021). What the reproductive number R_0 can and cannot tell us about COVID-19 dynamics. *Theoretical Population Biology*.

van den Driessche, P. and Watmough, J. (2002). Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Mathematical biosciences*, 180(1-2):29–48.

Appendix

5.1 Model and calculation of \mathcal{R}_0

The model in the form of a system of ordinary differential equations is

$$dS_u/dt = -\Lambda S_u - F_S S_u + \omega S_n, \quad (\text{A1a})$$

$$dS_n/dt = -(1 - \theta_w)\Lambda S_n + (1 - p_S)F_S S_u - \omega S_n, \quad (\text{A1b})$$

$$dS_p/dt = -(1 - \theta_w)\Lambda S_p + p_S F_S S_u - \omega S_p, \quad (\text{A1c})$$

$$dS_c/dt = -(1 - \theta_c)\Lambda S_c + \omega S_p, \quad (\text{A1d})$$

$$dI_u/dt = \Lambda S_u - F_I I_u + \omega I_n - \gamma I_u, \quad (\text{A1e})$$

$$dI_n/dt = (1 - \theta_w)\Lambda S_n + (1 - p_I)F_I I_u - \omega I_n - \gamma I_n, \quad (\text{A1f})$$

$$dI_p/dt = (1 - \theta_w)\Lambda S_p + p_I F_I I_u - \omega I_p - \gamma I_p, \quad (\text{A1g})$$

$$dI_c/dt = (1 - \theta_c)\Lambda S_c + \omega I_p - \gamma I_c, \quad (\text{A1h})$$

$$dR_u/dt = \gamma I_u - F_R R_u + \omega R_n, \quad (\text{A1i})$$

$$dR_n/dt = \gamma I_n + (1 - p_R)F_R R_u - \omega R_n, \quad (\text{A1j})$$

$$dR_p/dt = \gamma I_p + p_R F_R R_u - \omega R_p, \quad (\text{A1k})$$

$$dR_c/dt = \gamma I_c + \omega R_p, \quad (\text{A1l})$$

$$dN/dt = \omega(S_n + I_n + R_n), \quad (\text{A1m})$$

$$dP/dt = \omega(I_p + R_p), \quad (\text{A1n})$$

where parameters are specified in Table 1. The next generation matrix for this model is $G = FV^{-1}$, where matrix F represents the inflow of new infection to the infected compartments and matrix V represents the flow in the infected compartments when the population is totally susceptible. Matrices F and V are

$$F = \beta/N_0 \begin{bmatrix} S_u^* & (1 - \theta_w) S_u^* & (1 - \theta_w) S_u^* & (1 - \theta_c) S_u^* \\ (1 - \theta_w) S_n^* & (1 - \theta_w)^2 S_n^* & (1 - \theta_w)^2 S_n^* & (1 - \theta_w)(1 - \theta_c) S_n^* \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \end{bmatrix} \quad (\text{A2})$$

$$= \beta/N_0 \begin{bmatrix} S_u^* \\ (1 - \theta_w) S_n^* \\ 0 \\ 0 \end{bmatrix} [1, 1 - \theta_w, 1 - \theta_w, 1 - \theta_c], \text{ and} \quad (\text{A3})$$

$$V = \begin{bmatrix} \hat{F}_I + \gamma & -\omega & 0 & 0 \\ -(1 - p_I)\hat{F}_I & \omega + \gamma & 0 & 0 \\ -p_I\hat{F}_I & 0 & \omega + \gamma & 0 \\ 0 & 0 & -\omega & \gamma \end{bmatrix}. \quad (\text{A4})$$

The matrix inverse of V is

$$V^{-1} = \frac{1}{\gamma C} \begin{bmatrix} \gamma(\omega + \gamma)^2 & \gamma\omega(\omega + \gamma) & 0 & 0 \\ \gamma(\omega + \gamma)(1 - p_I)\hat{F}_I & \gamma(\omega + \gamma)(\hat{F}_I + \gamma) & 0 & 0 \\ \gamma(\omega + \gamma)p_I\hat{F}_I & \gamma\omega p_I\hat{F}_I & C\gamma/(\omega + \gamma) & 0 \\ \omega(\omega + \gamma)p_I\hat{F}_I & \omega^2 p_I\hat{F}_I & C\omega/(\omega + \gamma) & C \end{bmatrix}, \quad (\text{A5})$$

where $C = (\gamma(\omega + \gamma) + (\gamma + \omega p_I)\hat{F}_I)(\omega + \gamma)$ and \hat{F}_I is the *per capita* testing rate for the infected people and represented in Eq. (5). Note that all the columns of matrix V^{-1} sum up to $1/\gamma$.

The particular form of F with two rows of zeros at the bottom results in the following blocked form of matrix G .

$$G = \begin{bmatrix} G_{11} & G_{12} \\ 0 & 0 \end{bmatrix}, \quad (\text{A6})$$

where both blocked matrices G_{11} and G_{12} are 2 by 2. Given the upper triangular form of matrix G , the basic reproduction number \mathcal{R}_0 (defined as the spectral radius of matrix G) is only determined by the blocked matrix G_{11} ,

$$G_{11} = \frac{\beta}{\gamma C} \begin{bmatrix} (\omega - \rho)/\omega \\ (1 - \theta_w)\rho/\omega \end{bmatrix} \begin{bmatrix} 1, 1 - \theta_w, 1 - \theta_w, 1 - \theta_c \end{bmatrix} \begin{bmatrix} \gamma(\omega + \gamma)^2 & \gamma\omega(\omega + \gamma) \\ \gamma(\omega + \gamma)(1 - p_I)\hat{F}_I & \gamma(\omega + \gamma)(\hat{F}_I + \gamma) \\ \gamma(\omega + \gamma)p_I\hat{F}_I & \gamma\omega p_I\hat{F}_I \\ \omega(\omega + \gamma)p_I\hat{F}_I & \omega^2 p_I\hat{F}_I \end{bmatrix}. \quad (\text{A7})$$

It is notable that matrix F (A2) has rank one and consequently G_{11} does so. That is G_{11} has only one non-zero eigenvalue which is \mathcal{R}_0 .

The expression of \mathcal{R}_0 has a complicated form with all of the model parameters involved. This expression can be simplified and represented given the specific form of matrix G_{11} (A7). For the purpose of simplicity we present \mathcal{R}_0 in the manuscript in terms of expressions A , B and C , specified in (8). This is intended to show that \mathcal{R}_0 decreases as the strength of isolation, shown by θ_w and θ_c , increases.

It remains hard to show that the reproduction number \mathcal{R}_0 is decreasing with respect to *per capita* testing intensity, ρ , and the speed of the test return, ω , for the feasible ranges of the parameters, that is

$$\omega > 0, \quad (\text{A8})$$

$$0 \leq \rho < \omega, \quad (\text{A9})$$

$$0 \leq \theta_w \leq \theta_c \leq 1, \quad (\text{A10})$$

$$\frac{w_I}{w_S} \geq 1. \quad (\text{A11})$$

One way to do such an analysis is based on the fact that ρ is *per capita* rate so for a large population size, $N_0 \gg 1$, ρ is very small or close to 0, comparing to N_0 . This provides a base to linearly approximate \mathcal{R}_0 when ρ is close to 0, and use this approximation to analyze

the behaviour of \mathcal{R}_0 with respect to ω (see section 5.3). In the next section we provide an equivalent representation of \mathcal{R}_0 to provide a ground to prove that more testing intensity decreases \mathcal{R}_0 for a general range of parameters.

5.2 More testing intensity may decreases \mathcal{R}_0

This is to provide a mathematical materials to prove that $\frac{\partial}{\partial \rho} \Delta$ can be positive or negative, with Δ defined in Eq. (8), and thus $\frac{\partial}{\partial \rho} \mathcal{R}_0 < 0$, where \mathcal{R}_0 is the basic reproduction number, given in Eq. (6). We can rewrite matrix G_{11} in (A7) in the following form to simplify the calculations.

$$G_{11} = \frac{\beta}{\gamma C} \begin{bmatrix} S_u^*/N_0 \\ (1 - \theta_w) S_n^*/N_0 \end{bmatrix} [C - C_1, C - C_1 - C_2], \quad (\text{A12})$$

where C is the same as the one in Eq. (8), i.e.,

$$C = (\omega + \gamma)(\gamma(\omega + \gamma) + (\omega p_I + \gamma) \hat{F}_I),$$

and C_1 and C_2 are

$$C_1 = (\omega + \gamma)(\theta_w \gamma + \theta_c \omega p_I) \hat{F}_I, \quad (\text{A13})$$

$$C_2 = (\omega + \gamma) \gamma^2 \theta_w + (\theta_w - \theta_c) \gamma \omega p_I \hat{F}_I, \quad (\text{A14})$$

where \hat{F}_I is given in Eq. (5). Note that for analysis brevity, we let $N_0 = 1$, thus S_u^* and S_n^* are in the scale of 0 to 1. \mathcal{R}_0 is in the same form as in Eq. (6)

$$\mathcal{R}_0 = \frac{\beta}{\gamma} (1 - \Delta),$$

where

$$\Delta = \frac{1}{C} (C_1 S_u^* + ((C_1 + C_2)(1 - \theta_w) + C \theta_w) S_n^*). \quad (\text{A15})$$

The first goal is to explore how changes in isolation, θ_w and θ_c , affects \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \theta_w}$ and $\frac{\partial \mathcal{R}_0}{\partial \theta_c}$. We start with simplifying Δ (A15) by factoring θ_w and θ_c in Eq. (A15). Thus, Δ can be rewritten as

$$\Delta = \frac{1}{C} \left(-D_1 S_n^* \theta_w^2 + (-\omega^2 p_I \hat{F}_I S_n^* \theta_c + D_2 S_n^* + \gamma \hat{F}_I (\omega + \gamma)) \theta_w + (\omega + \gamma S_u^*) \omega p_I \hat{F}_I \theta_c \right), \quad (\text{A16})$$

where

$$D_1 = (\omega + \gamma) \gamma^2 + (\omega + \gamma + \omega p_I) \gamma \hat{F}_I, \quad (\text{A17})$$

$$D_2 = (3\omega + 2\gamma) \gamma^2 + (\omega + \gamma + 2\omega p_I) \gamma \hat{F}_I + (\gamma + p_I \hat{F}_I) \omega^2. \quad (\text{A18})$$

Δ , Eq. (A16), is linear in θ_c with a positive coefficient given by

$$1/C (\gamma S_u^* + \omega(1 - \theta_w S_u^*)) \omega p_I \hat{F}_I.$$

258 This results in increasing Δ , thus decreasing \mathcal{R}_0 with respect to θ_c , that is $\frac{\partial \mathcal{R}_0}{\partial \theta_c} \leq 0$. Note
 259 that C is independant of θ_c and θ_w .

260 With a similar logic, Δ (A16) is a concave-down quadratic equation in θ_w , given by

$$1/C \left(-D_1 S_n^* \theta_w^2 + (-\omega^2 p_I \hat{F}_I S_n^* \theta_c + D_2 S_n^* + \gamma \hat{F}_I (\omega + \gamma)) \theta_w \right). \quad (\text{A19})$$

We show that the feasible range of θ_w lies between 0 and the vertex of this parabola where the parabola is increasing in θ_w , and so does Δ which results in inferring $\frac{\partial \mathcal{R}_0}{\partial \theta_w} \leq 0$. It is enough to show that partial derivative of the expression (A19) with respect to θ_w at $\theta_w = 1$ is non-negative. It follows that

$$\left. \frac{\partial \Delta}{\partial \theta_w} \right|_{\theta_w=1} = 1/C \left((D_2 - 2D_1 - \omega^2 p_I \hat{F}_I \theta_c) S_n^* + \gamma \hat{F}_I (\omega + \gamma) \right) \quad (\text{A20})$$

$$= 1/C \left((\gamma(\omega + \gamma) + \gamma\omega^2 + (1 - \theta_c)\omega^2 p_I \hat{F}_I) S_n^* + \gamma(\omega + \gamma) \hat{F}_I (1 - S_n^*) \right), \quad (\text{A21})$$

261 which is a positive quantity, given that θ_c and S_n^* vary between 0 and 1.

262 **The second goal** is to explore how changes in *per capita* testing intensity ρ affects \mathcal{R}_0 .
 263 Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \rho}$, which specifically depends on $\frac{\partial \Delta}{\partial \rho}$.
 264 We use the derived expressions for S_u^* and S_n^* , given by Eqs. (4), in Δ (A16). Also, we define
 265 $\phi = \hat{F}_S = \frac{\rho\omega}{\omega - \rho}$, to reparametrize ρ . This is mainly to avoid singularity in \hat{F}_I (5), when testing
 266 intensity ρ is very close to the rate of test return ω . Thus, ρ is reparametrized as

$$\rho = \frac{\omega\phi}{\omega + \phi}. \quad (\text{A22})$$

This one-to-one monotonic reparametrization enables us to simplify the mathematical expressions and explore the simpler $\frac{\partial \Delta}{\partial \phi}$ instead of the complicated $\frac{\partial \Delta}{\partial \rho}$. The derivative is

$$\partial \Delta / \partial \phi = \frac{1}{d_3} (a_3 \phi^2 + b_3 \phi + c_3), \quad (\text{A23})$$

where

$$\begin{aligned} a_3 = \frac{w_I}{w_S} & \left(\left((\theta_w p_I^2 - \theta_c p_I^2 \theta_w) \omega^3 + (2 \theta_w p_I^2 - \theta_c p_I^2 - p_I \theta_w^2 - \theta_c p_I \theta_w - p_I^2 \theta_w^2 + 2 \theta_w p_I) \gamma \omega^2 \right. \right. \\ & + (-2 p_I \theta_w^2 - \theta_c p_I + 3 \theta_w p_I - \theta_w^2 + \theta_w) \gamma^2 \omega + (\theta_w - \theta_w^2) \gamma^3 \Big) \frac{w_I}{w_S} + (-\theta_c p_I \theta_w + \theta_c p_I) \gamma \omega^2 + \\ & \left. \left. (\theta_w + \theta_c p_I - \theta_w^2 - \theta_c p_I \theta_w) \gamma^2 \omega + (\theta_w - \theta_w^2) \gamma^3 \right), \quad (\text{A24}) \right) \end{aligned}$$

$$b_3 = 2 \frac{w_I}{w_S} (\omega + \gamma) \gamma \left((\omega + \gamma + \omega p_I) (2 - \theta_w) \gamma \theta_w + (1 - \theta_w) \omega^2 p_I \theta_c + \omega^2 p_I \theta_w \right), \quad (\text{A25})$$

$$c_3 = (\omega + \gamma)^2 \gamma \left((2 - \theta_w) \gamma^2 \theta_w + (1 + \frac{w_I}{w_S}) \omega \gamma \theta_w + \frac{w_I}{w_S} \omega^2 p_I \theta_c \right), \quad (\text{A26})$$

$$d_3 = \frac{(\omega + \gamma)}{\omega} \left((\omega p_I + \gamma) \frac{w_I}{w_S} \phi + (\omega + \gamma) \gamma \right)^2 (\omega + \phi)^2. \quad (\text{A27})$$

Note that $\phi \geq 0$, also b_3 , c_3 and d_3 are all positive. However a_3 can be positive or negative. If $a_3 \geq 0$, $\partial\Delta/\partial\phi \geq 0$ for all feasible range of parameters, thus $\frac{\partial}{\partial\rho}\mathcal{R}_0 \leq 0$. If $a_3 < 0$, then the quadratic expression in the numerator of (A23) has a positive root, ϕ^* , such that for $\phi > \phi^*$, $\partial\Delta/\partial\phi < 0$. An example of this counter-vailing effect of ρ on \mathcal{R}_0 occurs when $\theta_w = 0$ and $\theta_c = 1$. This is illustrated in the top-right panel of the Fig. 3 panel (b), where the strength of isolation for awaiting people is the least, but the most for the confirmed cases. In this case

$$a_3 = \frac{w_I}{w_S} \omega \gamma p_I ((\omega + \gamma) - \frac{w_I}{w_S} (\omega p_I + \gamma)).$$

Specifically, in the case of targeted testing which is identified with $\frac{w_I}{w_S} > 1$, and using a perfect sensitive test, thus $p_I = 1$, there exists a range for ρ over which $\frac{\partial\mathcal{R}_0}{\partial\rho} \leq 0$. Note that ρ and ω have a similar mechanism in delaying people to get into I_c , thus we would expect to see the non-trivial counter-vailing effect of these two parameters on \mathcal{R}_0 .

5.3 rate of returning tests

The third goal is to explore how changes in the rate of test return ω affects \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial\mathcal{R}_0}{\partial\omega}$, which specifically depends on $\frac{\partial\Delta}{\partial\omega}$. We use the linearization of \mathcal{R}_0 around $\rho = 0$ to show that there a non-monotonic relationship between \mathcal{R}_0 and ω . The Taylor expansion of Δ at $\rho = 0$ is

$$\Delta = \frac{\rho}{\omega \gamma (\omega + \gamma)} \left(\frac{w_I}{w_S} \omega^2 p_I \theta_c + \left(\frac{w_I}{w_S} + 1 \right) \gamma \omega \theta_w + \gamma^2 \theta_w (2 - \theta_w) \right). \quad (\text{A28})$$

This results in

$$\frac{\partial\Delta}{\partial\omega} = \frac{\rho}{\omega^2 (\omega + \gamma)^2} \left(\left(p_I \frac{w_I}{w_S} \theta_c - \left(1 + \frac{w_I}{w_S} \right) \theta_w \right) \omega^2 + 2 \theta_w \gamma (\theta_w - 2) \omega + \theta_w \gamma^2 (\theta_w - 2) \right), \quad (\text{A29})$$

around $\rho = 0$. **[Ali: I stoped here!]**

Perhaps counter-intuitively, the equation above does not predict that \mathcal{R}_0 is monotone decreasing with respect to ω . In other words; our model does not predict that returning test results more rapidly *always* lower \mathcal{R}_0 . In order to gain insight into this intriguing behavior, we examine the zeroes of $\frac{\partial\mathcal{R}_0}{\partial\omega}(\omega)$. Defining the following quantity, Q , will help us write the roots of $\partial\mathcal{R}_0/\partial\omega$ neatly as follows.

$$Q = \frac{w_I}{w_S} \left(1 - \frac{n_t - 1}{n_w - 1} p_I \right). \quad (\text{A30})$$

With that in mind, we can write the roots of $\partial\mathcal{R}_0/\partial\omega$ as

$$\omega_1 = \frac{\gamma}{-\sqrt{1-Q} - 1} \quad (\text{A31})$$

$$\omega_2 = \frac{\gamma}{\sqrt{1-Q} - 1}. \quad (\text{A32})$$

Note that the zeroes are real if and only if $Q < 1$. Note that have $\theta_c > \theta_w$, so if $p_I \approx 1$, we will have $Q < 0 < 1$. Thus, if we assume near-perfect test sensitivity, ω_1 and ω_2 will be real.

Assuming ω_1, ω_2 are real, it is easy to confirm that $\omega_1 < 0$ by looking at the denominator. To see that $\omega_2 > 0$, recall that $Q < 0$, so $\sqrt{1-Q} > 1$ and so $\sqrt{1-Q} - 1 > 0$. Knowing that $\omega_1 < 0$, the only root of interest (i.e., biologically relevant quantity) is ω_2 .

We can prove that $\partial \mathcal{R}_0 / \partial \omega > 0$ when $\omega \in (0, \omega_2)$ and $\partial \mathcal{R}_0 / \partial \omega < 0$ when $\omega \in (\omega_2, \infty)$ by computing the limits of $\partial \mathcal{R}_0 / \partial \omega$ at 0 and ∞ respectively. So it follows that \mathcal{R}_0 has a global maximum with respect to ω at $\omega = \omega_2$.

Now we want to characterize the parameter regions on which $\partial \mathcal{R}_0 / \partial \omega < 0$ (i.e., the conditions under which returning test results more rapidly is favorable). By the previous analysis, this is equivalent to solving for $\omega > \omega_2$. So

$$\begin{aligned} \omega &> \omega_2 \\ \omega &> \frac{\gamma}{\sqrt{1-Q} - 1} \\ \sqrt{1-Q} &> \frac{\gamma}{\omega} + 1 \end{aligned} \tag{A33}$$

$$1 - Q > \left(\frac{\gamma}{\omega} + 1\right)^2. \tag{A34}$$

Substituting in Q from (A30) we have

$$1 - \frac{w_I}{w_S} \left(1 - \frac{n_t - 1}{n_\omega - 1} P_i\right) > \left(\frac{\gamma}{\omega} + 1\right)^2 \tag{A35}$$

$$- \frac{w_I}{w_S} \left(1 - \frac{n_t - 1}{n_\omega - 1} P_i\right) > \left(\frac{\gamma}{\omega} + 1\right)^2 + 1 \tag{A36}$$

$$\frac{w_I}{w_S} \left(\frac{1 - n_t}{1 - n_\omega} P_i - 1\right) > \left(\frac{\gamma}{\omega} + 1\right)^2 + 1. \tag{A37}$$

Since all steps in deriving (A37) are reversible, (A37) gives a necessary and sufficient condition for $\omega > \omega_2$, which characterizes when returning tests more rapidly would cause a decrease in \mathcal{R}_0 .

5.4 On Testing Rate and Numerical Singularity

In this work, we didn't do any numerical solutions for the trajectories in our analysis. However, if one tries to do so there would be a singularity issue to deal with. Specifically, the numerical singularity issue with the chosen σ (1) is that the population in S compartments appeared to blow up when the DFE is achieved. This is once the only untested people are susceptibles, the FOI will become $\Lambda = 0$, testing rate $F_s = \rho N_0 / S_u$. Thus, the first equation of the model (A1) will become $dS_u / dt = -\rho N_0 + \omega S_u$. Thus changes in S_u will be no longer dependent on S_u with a linear rate of leaving the S_u compartment. IN fact the testing rate, σ , should be formulated such that people from the untested compartments will not be tested if they are not there. One way to fix this issue, is to consider a maximum testing rate, τ (1/day). In general, we want to test at a rate of ρ across the whole population. This won't always be possible, so we impose a maximum rate of τ per testable person and redefine $\sigma = \frac{\tau \rho N_0}{\tau W + \rho N_0}$, with the assumption that $\tau \gg \rho$. This alteration in σ , does not change any results related to \mathcal{R}_0 , thus we only impose it in the simulation of the epidemic dynamic.

5.5 Expensive vs. cheap tests

The use of tests cheaper than RT-PCR has been proposed as a potential strategy for containing the COVID-19 pandemic. While cheaper tests may be less sensitive and reliable than RT-PCR, they allow for broader and more intense testing. In the analysis below, we compare the \mathcal{R}_0 predicted by our model depending on the testing strategy.

Consider a test that allows us to test at rate ρ_1 and has sensitivity $P_{i,1}$, and another test that allows us to test at ρ_2 and has sensitivity $P_{i,2}$. Suppose that $\rho_1 > \rho_2$. Recall that the linearization of \mathcal{R}_0 around $\rho \approx 0$ is given by

$$\mathcal{R}_0 \approx \beta/\gamma + \frac{\beta\rho}{\omega(\omega + \gamma)\gamma^2 w_S} \left(\gamma(-\theta_w)(\gamma w_S + \omega w_I) + (-\theta_c)p_I w_I \omega^2 \right).$$

Treating \mathcal{R}_0 as a function of ρ and P_i , we can reduce the inequality

$$\mathcal{R}_0(\rho_2, P_{i,2}) < \mathcal{R}_0(\rho_1, P_{i,1})$$

into

$$\begin{aligned} & \rho_1 \left(\gamma(-\theta_w)(\gamma w_S + \omega w_I) + (-\theta_c)p_{I,1} w_I \omega^2 \right) - \rho_2 \left(\gamma(-\theta_w)(\gamma w_S + \omega w_I) + (-\theta_c)p_{I,2} w_I \omega^2 \right) > 0 \\ & \vdots \\ & \frac{\rho_2 P_{i,2} - \rho_1 P_{i,1}}{\rho_1 - \rho_2} > \frac{\theta_w}{\theta_c} \cdot \frac{\gamma(\gamma w_S + \omega w_I)}{\omega^2 w_I} \end{aligned} \quad (\text{A38})$$

Note that the RHS is positive, thus a necessary condition for the inequality above to hold is that $\rho_2 P_{i,2} > \rho_1 P_{i,1}$, equivalently

$$\frac{P_{i,2}}{P_{i,1}} > \frac{\rho_1}{\rho_2}. \quad (\text{A39})$$

To state an example of this, if test A is three times as expensive as test B (and hence one can test three times as many people with test B), using test A rather than B will be favorable only if test A is at least 3 times more sensitive than test B . Note that this is a necessary but not sufficient condition, so even if test A is three times more sensitive, it is still possible for test B to be more effective.

Eq. (A38) tells us precisely when a test corresponding to $\rho_2, P_{i,2}$ will yield a lower \mathcal{R}_0 than a test corresponding to $\rho_1, P_{i,1}$, where $\rho_1 > \rho_2$. Some of the qualitative *trends* that favor test 2 (the higher-sensitivity test) include

- individuals who test positive self-isolate much more than individuals who are waiting for their test result.
- the time it takes to return tests is much shorter than the mean infectious period.
- the testing intensity is much greater for infected individuals than susceptible individuals.